

IPAMC/14(IV)/26-27

May 14, 2026

To,
National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex, Bandra(E),
Mumbai - 400 051.

Sub: Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations 2011

Dear Sir/Madam,

This is to inform you that ICICI Prudential Mutual Fund (the Fund) including iSIF under its various schemes/investment strategies holds equity shares of Windlas Biotech Ltd.(the Company), listed on your stock Exchange.

The Fund under its schemes/investment strategies has carried out sale of 1,44,516 shares of the Company on May 13, 2026. As a result, the shareholding of the Fund has decreased by more than 2% of the paid-up capital of the Company as compared to previous disclosure on July 30, 2024 for 6.96%.

It may be further noted that the schemes/investment strategies of the Fund have carried out net sale of 5,40,642 shares of the Company from the last filing submitted on July 30, 2024 (for positions held as on July 29, 2024).

The holding by schemes/investment strategies of the Fund are from an investment perspective and not with the objective of seeking any controlling interest. However, the disclosures in this regard as required under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 is enclosed herewith.

Thanking you.

For ICICI Prudential Asset Management Company Limited



Rakesh Shetty
Chief Compliance Officer & Company Secretary



Format for Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

PART – A – Details of Sale

Name of the Target Company (TC)	Windlas Biotech Ltd..		
Name(s) of the acquirer/Seller and Person Acting in Concert (PAC) with the acquirer	ICICI Prudential Mutual Fund		
Whether the acquirer/Seller belongs to Promoter/Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited, National Stock Exchange of India Limited		
Details of the acquisition/disposal as follows	Number	% w.r.t. total shares /voting capital wherever applicable	% w.r.t. total diluted share / voting capital of the TC
Before the sale under consideration, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	14,53,777	6.96	6.62
b) Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others)	--	--	--
c) Voting rights (VR) otherwise than by equity shares	--	--	--
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	--	--	--
e) Total (a+b+c+d)	14,53,777	6.96	6.62
Details of sale (Net)			
a) Shares carrying voting rights sold.	5,40,642	2.63#	2.46
b) VRs acquired otherwise than by equity shares	--	--	--
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired	--	--	--
d) Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others)	--	--	--
e) Total (a+b+c+d)	5,40,642	2.63#	2.46



MP

After the sale, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	9,13,135	4.33	4.16
b) Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others)	--	--	--
c) Shares pledged with the acquirer	--	--	--
d) VRs otherwise than by equity shares	--	--	--
e) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	--	--	--
e) Total (a+b+c+d)	9,13,135	4.33	4.16
(Note: the percentages have been rounded off to the nearest number)			
Mode of sale (e.g. open market/public issue/rights issue/preferential allotment/inters transfer/encumbrance, etc.)	Open Market		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	N.A.		
Date of sale of/date of receipt of intimation of allotment of shares/VR/warrants/convertible securities/any other instrument that entitles the acquirer/seller to receive shares in the TC.	The aforesaid net disposal was made during the period July 30, 2024 to May 13, 2026		
Equity share capital/total voting capital of the TC before the said disposal	₹ 10,45,01,555 comprising of 2,09,00,311 shares of face value ₹5/- each		
Equity share capital/total voting capital of the TC after the said disposal	₹ 10,55,31,145 comprising of 2,11,06,229 shares of face value ₹5/- each		
Total diluted share/voting capital of the TC after the said disposal	₹ 10,98,59,465 comprising of 2,19,71,893 shares of face value ₹5/- each		



APR


Note. —

Total share capital/ voting capital and diluted share/voting capital to be taken as per the latest filing done by the Company to the Stock Exchanges.

Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Diluted share/voting capital does not include ESOPs granted and outstanding.

(#) The paid-up capital as on May 13, 2026, has increased as compared to paid up capital as on last filing date i.e., July 30, 2024 and hence the percentage under column "% w.r.t. total shares/voting capital" i.e. 2.63% is calculated as derived figure by taking difference of holding before the net disposal and holding after the net disposal.



Rakesh Shetty
Chief Compliance Officer & Company Secretary

Place : Mumbai

Date : May 14, 2026